Risk-benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab.
Jun Won ParkJeffrey R CurtisSe Rim ChoiMin Jung KimYou-Jung HaEun Ha KangYun Jong LeeEun Bong LeePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
The benefit associated with primary PJP prophylaxis overweighs the risk of severe AEs in patients receiving rituximab and concomitant high-dose glucocorticoid treatment. This article is protected by copyright. All rights reserved.